2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia BXCL501, Placebo film - Agitation, Dementia | Phase 2 | Terminated | BioXcel Therapeutics Inc | 5 | 2022-02-08 | 2026-08-11 |
| A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression MP-101, Placebo - Psychosis, Dementia | Phase 2 | Terminated | Mediti Pharma Inc. | 81 | 2017-05-04 | 2021-04-01 |
Dementia (2) · Psychomotor Agitation (2) · Aggression (1) · Alzheimer Disease (1) · Psychotic Disorders (1)
Aberrant Motor Behavior in Dementia (2) · Behavior (2) · Behavioral Symptoms (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Dyskinesias (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurocognitive Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Psychomotor Disorders (2) · Signs and Symptoms (2) · Neurodegenerative Diseases (1)
Dexmedetomidine (1) · LY2812223 (1)
BioXcel Therapeutics Inc (1) · Mediti Pharma Inc. (1)
United States (2) · Canada (1)
BioXcel MM, MD (1)